Labcorp OnDemand Diabetes Risk Test: There is a new and convenient way for millions of individuals to assess whether they are at risk for developing diabetes. Labcorp (NYSE: LH), a leading global life sciences company, is making screening for diabetes easier with the launch of an at-home collection kit through Labcorp OnDemand™ that measures hemoglobin A1c (HbA1c) from a small blood sample.
Labcorp is the only commercial laboratory to provide HbA1c testing using a new, cutting-edge collection device from Weavr Health, a diagnostics company that provides remote biofluid collection devices to extend access to health and wellness testing.
In addition, Labcorp is the first and only laboratory to receive approval from the New York State Clinical Laboratory Evaluation Program for testing using the Weavr Velvet™ blood collection device. This allows for the Labcorp OnDemand Diabetes Risk test to be available nationwide.
“Diabetes is a serious disease affecting millions of people in the United States,” said Dr. Brian Caveney, chief medical officer and president, Labcorp Diagnostics. “Our Labcorp OnDemand Diabetes Risk Test at-home collection kit now makes it easier for consumers to understand their diabetes risk and health status using an innovative and approved collection device. This test offers a convenient way for more people to manage their health and stay informed, so they can seek treatment that may lead to better health outcomes.”
One of the primary ways to screen for diabetes and prediabetes and monitor the quality of treatment is through a HbA1c test. According to the U.S. Centers for Disease Control and Prevention, 96 million adults have prediabetes in the United States and 8 in 10 of them are not aware they have it. More than 37 million people are living with diabetes, and 1 in 5 go undiagnosed.
The Labcorp OnDemand Diabetes Risk test uses a dried blood technology to give a snapshot of the body’s average blood sugar levels over time. With a prick of the finger and a few drops of blood, consumers can be empowered to proactively monitor their health status on a regular basis from the comfort of their home.
According to a recent study published by Clinical Chemistry, results from samples collected via the Weavr Velvet device are over 97% accurate when compared to results from a traditional blood draw. Through an equity investment made by Labcorp, the device was co-developed for HbA1c by the two companies with Weavr remaining the device owner.
“Through our collaboration with Labcorp, we are able to bring safe, efficient testing to doorsteps across the country,” said Linh Hoang, chief executive officer of Weavr Health. “Our goal is to create innovative testing solutions so that people in all communities have access to life-saving diagnostics and feel empowered to take control of their health.”
Labcorp OnDemand Diabetes Risk at-home collection kits are available to purchase at Diabetes Risk (HbA1c) At-Home Collection Test | Labcorp OnDemandand are not covered by health insurance coverage.